SCHEMBL1287307

SCHEMBL1287307

COC(=O)c1ccc(CN(C2COC(C)(C)OC2)S(=O)(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.41
PSEN1 P49768 4/20 0.39
PSEN2 P49810 4/20 0.39
APH1B Q8WW43 4/20 0.39
NCSTN Q92542 4/20 0.39
APH1A Q96BI3 4/20 0.39
PSENEN Q9NZ42 4/20 0.39
MAPT P10636 3/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HDAC6 Q9UBN7 6/20 0.36
HDAC8 Q9BY41 5/20 0.36
HDAC11 Q96DB2 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.34
HDAC3 O15379 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
P2RY12 Q9H244 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287602 0.90 PSEN1 (0.36) RAB9APSEN1PSEN2APH1BNCSTN
SCHEMBL1287498 0.89 MEN1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1287427 0.83 MAPT (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1287372 0.75 RAB9A (0.48) RAB9APSEN1PSEN2APH1BNCSTN
SCHEMBL1287984 0.73 RAB9A (0.46) RAB9APSEN1PSEN2APH1BNCSTN
SCHEMBL15387994 0.70 RAB9A (0.43) RAB9APSEN1PSEN2APH1BNCSTN
SCHEMBL15396076 0.69 RAB9A (0.44) RAB9APSEN1PSEN2APH1BNCSTN
SCHEMBL1287491 0.68 KMT2A (0.54) POLBSMN1; SMN2ALDH1A1CYP3A4CYP2C9
SCHEMBL14842437 0.67 HDAC8 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14842995 0.67 MEN1 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP RAB9A 2338/4885PSEN1 4/4885PSEN2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.